Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma

Journal of Neuro-Oncology

Volumn 114, Issue 3, 2013, Pages 339-344

  Jackson, Sadhana ^a   Patay, Zoltan ^a   Howarth, Robyn ^a   Pai Panandiker, Atmaram S ^a   Onar Thomas, Arzu ^a   Gajjar, Amar ^a,b   Broniscer, Alberto ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Diffuse; Glioma; Long term; Neurocognitive; Pontine; Survivors

Indexed keywords

6 O BENZYLGUANINE; CARBOPLATIN; CARMUSTINE; ETOPOSIDE; GEFITINIB; IMATINIB; LONAFARNIB; TEMOZOLOMIDE; VANDETANIB; VINCRISTINE;

BORDERLINE STATE; CANCER RADIOTHERAPY; CANCER SURVIVOR; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LONG TERM SURVIVAL; MALE; MEDICAL RECORD; MEDULLA OBLONGATA; MENTAL DEFICIENCY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PONTINE GLIOMA; REVIEW; TREATMENT OUTCOME; TUMOR GROWTH;

ADOLESCENT; BRAIN STEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; PROGNOSIS; SURVIVAL RATE; SURVIVORS;

EID: 84883165363     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1189-0     Document Type: Review

References (35)

1. Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241-248
2. Puget S, Philippe C, Bax DA et al (2012) Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One 7:e30313
3. Monje M, Mitra SS, Freret ME et al (2011) Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci USA 108:4453-4458
4. Broniscer A, Leite CC, Lanchote VL, Machado TM, Cristófani LM (2000) Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group. J Clin Oncol 18:1246-1253
5. Greenberg ML, Fisher PG, Freeman C et al (2005) Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a Pediatric Oncology Group phase I study. Pediatr Blood Cancer 45:644-648
6. Wagner S, Warmuth-Metz M, Emser A et al (2006) Treatment options in childhood pontine gliomas. J Neurooncol 79:281-287
7. Massimino M, Spreafico F, Biassoni V et al (2008) Diffuse pontine gliomas in children: changing strategies, changing results? a mono-institutional 20-year experience. J Neurooncol 87:355-361
8. Broniscer A, Baker JN, Tagen M et al (2010) Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 28:4762-4768
9. Haas-Kogan DA, Banerjee A, Poussaint TY et al (2011) Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol 13:298-306
10. Pollack IF, Stewart CF, Kocak M et al (2011) A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the pediatric brain tumor consortium. Neuro Oncol 13:290-297
11. Freeman CR, Bourgouin PM, Sanford RA, Cohen ME, Friedman HS, Kun LE (1996) Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The Pediatric Oncology Group. Cancer 77:555-562
12. Allen J, Siffert J, Donahue B et al (1999) A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer 86:1064-1069
13. Hargrave D, Chuang N, Bouffet E (2008) Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neurooncol 86:313-319
14. ®)) in children with diffuse intrinsic pontine glioma. Cancer 118:3607-3613
15. Barkovich AJ, Krischer J, Kun LE et al (1990/1991) Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg 16:73-83
16. Fischbein NJ, Prados MD, Wara W, Russo C, Edwards MS, Barkovich AJ (1996) Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. Pediatr Neurosurg 24:9-23
17. Wechsler D (2003) Wechsler intelligence scale for children. The Psychological Corporation, San Antonio
18. Wechsler D (2008) Wechsler adult intelligence scale. The Psychological Corporation, San Antonio
19. Woodcock RW, McGrew KS, Mather N (2001) Woodcock-Johnson tests of achievement III. Riverside Publishing, Itasca
20. Wechsler D (2002) Wechsler individual achievement test. The Psychological Corporation, San Antonio
21. Bryant BR, Wiederholt L, Bryant DP (2004) Gray diagnostic reading tests. PRO-ED Inc., Austin
22. Gioia GA, Isquith PK, Guy SC, Kenworthy L (2000) Behavior rating inventory of executive function. Psychological Assessment Resources Inc., Odessa
23. Sanford RA, Freeman CR, Burger P, Cohen ME (1988) Prognostic criteria for experimental protocols in pediatric brainstem gliomas. Surg Neurol 30:276-280
24. Fisher PG, Breiter S, Carson BS et al (2000) A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocytic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer 89:1569-1576
25. Pollack IF, Jakacki RI, Blaney SM et al (2007) Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a pediatric brain tumor consortium report. Neuro Oncol 9:145-160
26. 6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer 50:549-553
27. Kieran MW, Packer RJ, Onar A et al (2007) Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a pediatric brain tumor consortium study. J Clin Oncol 25:3137-3143
28. Broniscer A, Iacono L, Chintagumpala M et al (2005) Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer 103:133-139
29. Cohen KJ, Heideman RL, Zhou T et al (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol 13:410-416
30. Lezak MD, Howieson DB, Loring DW (2004) Neuropsychological assessment. Oxford University Press, New York
31. Garrard P, Bradshaw D, Jäger HR, Thompson AJ, Losseff N, Playford D (2002) Cognitive dysfunction after isolated brain stem insult. An underdiagnosed cause of long term morbidity. J Neurol Neurosurg Psychiatry 73:191-194
32. Hoffmann M, Watts A (1998) Cognitive dysfunction in isolated brainstem stroke: a neuropsychological and SPECT study. J Stroke Cerebrovasc Dis 7:24-31
33. Hoffmann M, Schmitt F (2004) Cognitive impairment in isolated subtentorial stroke. Acta Neurol Scand 109:14-24
34. Wu G, Broniscer A, McEachron TA et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251-253
35. Khuong-Quang DA, Buczkowicz P, Rakopoulos P et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124:439-447